Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

09-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The JAKPOT study

Kim Lauper discusses findings from the JAKPOT study, an international collaboration showing comparable JAK inhibitor and TNF inhibitor retention rates in real-world patients with rheumatoid arthritis (3:50).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

Related content

05-06-2020 | EULAR 2020 | Conference coverage | News

JAKPOT study takes a real-world look at JAK inhibitor retention vs TNF inhibitor

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase 3 trials
Image Credits